Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

The Hippo pathway effector TAZ induces TEAD-dependent liver inflammation and tumors.

Hagenbeek TJ, Webster JD, Kljavin NM, Chang MT, Pham T, Lee HJ, Klijn C, Cai AG, Totpal K, Ravishankar B, Yang N, Lee DH, Walsh KB, Hatzivassiliou G, de la Cruz CC, Gould SE, Wu X, Lee WP, Yang S, Zhang Z, Gu Q, Ji Q, Jackson EL, Lim DS, Dey A.

Sci Signal. 2018 Sep 11;11(547). pii: eaaj1757. doi: 10.1126/scisignal.aaj1757.

PMID:
30206136
2.

The tumor suppressor BAP1 cooperates with BRAFV600E to promote tumor formation in cutaneous melanoma.

Webster JD, Pham TH, Wu X, Hughes NW, Li Z, Totpal K, Lee HJ, Calses PC, Chaurushiya MS, Stawiski EW, Modrusan Z, Chang MT, Tran C, Lee WP, Chalasani S, Hung J, Sharma N, Chan S, Hotzel K, Talevich E, Shain A, Xu M, Lill J, Dixit VM, Bastian BC, Dey A.

Pigment Cell Melanoma Res. 2018 Aug 29. doi: 10.1111/pcmr.12735. [Epub ahead of print]

PMID:
30156010
3.

IFN-γ-induced chemokines are required for CXCR3-mediated T cell recruitment and anti-tumor efficacy of anti-HER2/CD3 bispecific antibody.

Li J, Ybarra R, Mak J, Herault A, De Almeida P, Arrazate A, Ziai J, Totpal K, Junttila MR, Walsh KB, Junttila TT.

Clin Cancer Res. 2018 Jun 27. pii: clincanres.1139.2018. doi: 10.1158/1078-0432.CCR-18-1139. [Epub ahead of print]

PMID:
29950350
4.

Relative Target Affinities of T-Cell-Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model.

Mandikian D, Takahashi N, Lo AA, Li J, Eastham-Anderson J, Slaga D, Ho J, Hristopoulos M, Clark R, Totpal K, Lin K, Joseph SB, Dennis MS, Prabhu S, Junttila TT, Boswell CA.

Mol Cancer Ther. 2018 Apr;17(4):776-785. doi: 10.1158/1535-7163.MCT-17-0657. Epub 2018 Jan 16.

PMID:
29339550
5.

Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing.

Li J, Stagg NJ, Johnston J, Harris MJ, Menzies SA, DiCara D, Clark V, Hristopoulos M, Cook R, Slaga D, Nakamura R, McCarty L, Sukumaran S, Luis E, Ye Z, Wu TD, Sumiyoshi T, Danilenko D, Lee GY, Totpal K, Ellerman D, Hötzel I, James JR, Junttila TT.

Cancer Cell. 2017 Mar 13;31(3):383-395. doi: 10.1016/j.ccell.2017.02.001. Epub 2017 Mar 2.

6.

Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice.

Lau J, Cheung J, Navarro A, Lianoglou S, Haley B, Totpal K, Sanders L, Koeppen H, Caplazi P, McBride J, Chiu H, Hong R, Grogan J, Javinal V, Yauch R, Irving B, Belvin M, Mellman I, Kim JM, Schmidt M.

Nat Commun. 2017 Feb 21;8:14572. doi: 10.1038/ncomms14572.

7.

An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.

Leong SR, Sukumaran S, Hristopoulos M, Totpal K, Stainton S, Lu E, Wong A, Tam L, Newman R, Vuillemenot BR, Ellerman D, Gu C, Mathieu M, Dennis MS, Nguyen A, Zheng B, Zhang C, Lee G, Chu YW, Prell RA, Lin K, Laing ST, Polson AG.

Blood. 2017 Feb 2;129(5):609-618. doi: 10.1182/blood-2016-08-735365. Epub 2016 Dec 1.

8.

Antitherapeutic antibody-mediated hepatotoxicity of recombinant human Apo2L/TRAIL in the cynomolgus monkey.

Zuch de Zafra CL, Ashkenazi A, Darbonne WC, Cheu M, Totpal K, Ortega S, Flores H, Walker MD, Kabakoff B, Lum BL, Mounho-Zamora BJ, Marsters SA, Dybdal NO.

Cell Death Dis. 2016 Aug 11;7(8):e2338. doi: 10.1038/cddis.2016.241.

9.

Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.

Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, Yan X, Clark R, Reyes A, Stefanich E, Mai E, Young J, Johnson C, Huseni M, Wang X, Chen Y, Wang P, Wang H, Dybdal N, Chu YW, Chiorazzi N, Scheer JM, Junttila T, Totpal K, Dennis MS, Ebens AJ.

Sci Transl Med. 2015 May 13;7(287):287ra70. doi: 10.1126/scitranslmed.aaa4802.

PMID:
25972002
10.

Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells.

Junttila TT, Li J, Johnston J, Hristopoulos M, Clark R, Ellerman D, Wang BE, Li Y, Mathieu M, Li G, Young J, Luis E, Lewis Phillips G, Stefanich E, Spiess C, Polson A, Irving B, Scheer JM, Junttila MR, Dennis MS, Kelley R, Totpal K, Ebens A.

Cancer Res. 2014 Oct 1;74(19):5561-71. doi: 10.1158/0008-5472.CAN-13-3622-T. Epub 2014 Sep 16.

11.

PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition.

Zhou W, Jubb AM, Lyle K, Xiao Q, Ong CC, Desai R, Fu L, Gnad F, Song Q, Haverty PM, Aust D, Grützmann R, Romero M, Totpal K, Neve RM, Yan Y, Forrest WF, Wang Y, Raja R, Pilarsky C, de Jesus-Acosta A, Belvin M, Friedman LS, Merchant M, Jaffee EM, Zheng L, Koeppen H, Hoeflich KP.

J Pathol. 2014 Dec;234(4):502-13. doi: 10.1002/path.4412. Epub 2014 Oct 6.

12.

Engineering upper hinge improves stability and effector function of a human IgG1.

Yan B, Boyd D, Kaschak T, Tsukuda J, Shen A, Lin Y, Chung S, Gupta P, Kamath A, Wong A, Vernes JM, Meng GY, Totpal K, Schaefer G, Jiang G, Nogal B, Emery C, Vanderlaan M, Carter P, Harris R, Amanullah A.

J Biol Chem. 2012 Feb 17;287(8):5891-7. doi: 10.1074/jbc.M111.311811. Epub 2011 Dec 27.

13.

A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies.

Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, Totpal K, Wong A, Lee CV, Stawicki S, Clark R, Fields C, Lewis Phillips GD, Prell RA, Danilenko DM, Franke Y, Stephan JP, Hwang J, Wu Y, Bostrom J, Sliwkowski MX, Fuh G, Eigenbrot C.

Cancer Cell. 2011 Oct 18;20(4):472-86. doi: 10.1016/j.ccr.2011.09.003.

14.

An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.

Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D, Li Y, Pitti R, Totpal K, Yee S, Ross S, Vernes JM, Lu Y, Adams C, Offringa R, Kelley B, Hymowitz S, Daniel D, Meng G, Ashkenazi A.

Cancer Cell. 2011 Jan 18;19(1):101-13. doi: 10.1016/j.ccr.2010.11.012.

15.

Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer.

Junttila TT, Parsons K, Olsson C, Lu Y, Xin Y, Theriault J, Crocker L, Pabonan O, Baginski T, Meng G, Totpal K, Kelley RF, Sliwkowski MX.

Cancer Res. 2010 Jun 1;70(11):4481-9. doi: 10.1158/0008-5472.CAN-09-3704. Epub 2010 May 18.

16.

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.

Qing J, Du X, Chen Y, Chan P, Li H, Wu P, Marsters S, Stawicki S, Tien J, Totpal K, Ross S, Stinson S, Dornan D, French D, Wang QR, Stephan JP, Wu Y, Wiesmann C, Ashkenazi A.

J Clin Invest. 2009 May;119(5):1216-29. doi: 10.1172/JCI38017. Epub 2009 Apr 20.

17.

Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.

Jin H, Yang R, Ross J, Fong S, Carano R, Totpal K, Lawrence D, Zheng Z, Koeppen H, Stern H, Schwall R, Ashkenazi A.

Clin Cancer Res. 2008 Dec 1;14(23):7733-40. doi: 10.1158/1078-0432.CCR-08-0670.

18.

Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake.

Shang Y, Mao Y, Batson J, Scales SJ, Phillips G, Lackner MR, Totpal K, Williams S, Yang J, Tang Z, Modrusan Z, Tan C, Liang WC, Tsai SP, Vanderbilt A, Kozuka K, Hoeflich K, Tien J, Ross S, Li C, Lee SH, Song A, Wu Y, Stephan JP, Ashkenazi A, Zha J.

Mol Cancer Ther. 2008 Sep;7(9):2599-608. doi: 10.1158/1535-7163.MCT-07-2401.

19.

Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.

Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S, Ross S, Deforge L, Koeppen H, Sagolla M, Compaan D, Lowman H, Hymowitz S, Ashkenazi A.

Cell Death Differ. 2008 Apr;15(4):751-61. doi: 10.1038/sj.cdd.4402306. Epub 2008 Jan 25.

20.

Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.

Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, Lee D, von Goetz M, Yee SF, Totpal K, Huw L, Katta V, Cavet G, Hymowitz SG, Amler L, Ashkenazi A.

Nat Med. 2007 Sep;13(9):1070-7. Epub 2007 Sep 2.

PMID:
17767167
21.

Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.

Daniel D, Yang B, Lawrence DA, Totpal K, Balter I, Lee WP, Gogineni A, Cole MJ, Yee SF, Ross S, Ashkenazi A.

Blood. 2007 Dec 1;110(12):4037-46. Epub 2007 Aug 27.

23.

Species-dependent serum interference in a sandwich ELISA for Apo2L/TRAIL.

DeForge LE, Shih DH, Kennedy D, Totpal K, Chuntharapai A, Bennett GL, Drummond JH, Siguenza P, Wong WL.

J Immunol Methods. 2007 Mar 30;320(1-2):58-69. Epub 2007 Jan 5.

PMID:
17280683
24.

Activation of the proapoptotic death receptor DR5 by oligomeric peptide and antibody agonists.

Li B, Russell SJ, Compaan DM, Totpal K, Marsters SA, Ashkenazi A, Cochran AG, Hymowitz SG, Sidhu SS.

J Mol Biol. 2006 Aug 18;361(3):522-36. Epub 2006 Jul 7.

PMID:
16859704
25.

Death-receptor activation halts clathrin-dependent endocytosis.

Austin CD, Lawrence DA, Peden AA, Varfolomeev EE, Totpal K, De Mazière AM, Klumperman J, Arnott D, Pham V, Scheller RH, Ashkenazi A.

Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10283-10288. doi: 10.1073/pnas.0604044103. Epub 2006 Jun 26. Erratum in: Proc Natl Acad Sci U S A. 2006 Sep 5;103(36):13560.

26.

Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling.

Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L, Pai R, Hymowitz SG, Ashkenazi A.

J Biol Chem. 2005 Jan 21;280(3):2205-12. Epub 2004 Nov 1.

27.

Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.

Jin H, Yang R, Fong S, Totpal K, Lawrence D, Zheng Z, Ross J, Koeppen H, Schwall R, Ashkenazi A.

Cancer Res. 2004 Jul 15;64(14):4900-5.

28.

Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors.

Xiang H, Fox JA, Totpal K, Aikawa M, Dupree K, Sinicropi D, Lowe J, Escandón E.

Oncogene. 2002 May 16;21(22):3611-9.

29.

Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.

LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D, Ashkenazi A.

Nat Med. 2002 Mar;8(3):274-81.

PMID:
11875499
30.
31.

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions.

Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, Hooley J, Sherwood S, Pai R, Leung S, Khan L, Gliniak B, Bussiere J, Smith CA, Strom SS, Kelley S, Fox JA, Thomas D, Ashkenazi A.

Nat Med. 2001 Apr;7(4):383-5. No abstract available.

PMID:
11283636
32.

Identification of multiple sources of charge heterogeneity in a recombinant antibody.

Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, Shire SJ, Bjork N, Totpal K, Chen AB.

J Chromatogr B Biomed Sci Appl. 2001 Mar 10;752(2):233-45.

PMID:
11270864
33.

Engineered antibodies with increased activity to recruit complement.

Idusogie EE, Wong PY, Presta LG, Gazzano-Santoro H, Totpal K, Ultsch M, Mulkerrin MG.

J Immunol. 2001 Feb 15;166(4):2571-5.

34.

Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc.

Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, Meng YG, Mulkerrin MG.

J Immunol. 2000 Apr 15;164(8):4178-84.

35.

A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL.

Hymowitz SG, O'Connell MP, Ultsch MH, Hurst A, Totpal K, Ashkenazi A, de Vos AM, Kelley RF.

Biochemistry. 2000 Feb 1;39(4):633-40.

PMID:
10651627
36.

Qualitative and quantitative differences in the cellular responses mediated through Fas antigen and tumor necrosis factor receptor.

Totpal K, Singh S, Lapushin R, Aggarwal BB.

J Interferon Cytokine Res. 1996 Mar;16(3):259-67.

PMID:
8697149
38.
40.
42.
43.

TNF and its receptor antibody agonist differ in mediation of cellular responses.

Totpal K, LaPushin R, Kohno T, Darnay BG, Aggarwal BB.

J Immunol. 1994 Sep 1;153(5):2248-57.

PMID:
8051422
44.

pp60v-src kinase overexpression leads to cellular resistance to the antiproliferative effects of tumor necrosis factor.

Aggarwal BB, Totpal K, Ali-Osman F, Budde RJ, Pocsik E.

FEBS Lett. 1994 May 30;345(2-3):219-24.

46.
47.
48.

In vitro selection of NIH-3T3 cells for resistance to lymphotoxin induces resistance to activated macrophages and enhances tumorigenicity in vivo.

Totpal K, Lapushin R, Ananthaswamy HN, Aggarwal BB.

Lymphokine Cytokine Res. 1991 Oct;10(5):359-67.

PMID:
1768739
49.
50.

Highly oncolytic adherent lymphocytes: therapeutic relevance for leukemia.

Lotzová E, Savary CA, Totpal K, Schachner J, Lichtiger B, McCredie KB, Freireich EJ.

Leuk Res. 1991;15(4):245-54.

PMID:
2030606

Supplemental Content

Loading ...
Support Center